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Pwo-Year Follow-Up of the
uantitative Angiographic and
olumetric Intravascular Ultrasound Analysis After
onpolymeric Paclitaxel-Eluting Stent Implantation
ate “Catch-Up” Phenomenon From ASPECT Study
uk-Woo Park, MD,* Myeong-Ki Hong, MD,* Gary S. Mintz, MD, FACC,‡ Cheol Whan Lee, MD,*
ong-Min Song, MD,* Ki-Hoon Han, MD,* Duk-Hyun Kang, MD,* Sang-Sig Cheong, MD,†
ae-Kwan Song, MD, FACC,* Jae-Joong Kim, MD,* Neil J. Weissman, MD, FACC,§
eong-Wook Park, MD, FACC,* Seung-Jung Park, MD, FACC*
eoul and GangNeung, Korea; New York, New York; and Washington, DC
OBJECTIVES This study used serial angiographic and intravascular ultrasound (IVUS) analysis to evaluate
the long-term efficacy of a nonpolymeric, paclitaxel-eluting stent coating on intimal
hyperplasia (IH) 2 years after implantation.
BACKGROUND Long-term efficacy of patients treated with nonpolymeric paclitaxel-eluting stents beyond 1
year has not been well determined.
METHODS Patients were randomized to placebo or 1 of 2 doses of paclitaxel (low dose, 1.28 g/mm2;
high dose, 3.10 g/mm2). Complete after-procedure, 6-month, and 2-year angiographic and
IVUS data were available in 53 patients (17, 17, and 19 patients, respectively).
RESULTS Baseline characteristics were similar among the 3 groups. Although 6-month minimal
luminal diameter (MLD) was significantly smaller in placebo compared with paclitaxel-
eluting stent patients (1.9  0.6 mm in placebo, 2.5  0.6 mm in low-dose, and 2.6  0.5
mm in high-dose patients, p  0.004), the MLDs at 2 years were similar (2.3  0.6 mm,
2.3  0.7 mm, and 2.0  0.8 mm, respectively, p  0.4). Despite a stepwise reduction in IH
accumulation at 6 months (23  18 mm3 in placebo, 14  11 mm3 in low-dose, and 10 
12 mm3 in high-dose, p  0.017), the increase of IH volume from 6 months to 2 years was
significantly greater in the high-dose patients (13  14 mm3 in high-dose vs. 4  7 mm3 in
low-dose patients, p  0.074; and vs. 1  13 mm3 in placebo, p  0.019). Late target lesion
revascularization (beyond 1 year) was performed in 2 high-dose patients.
CONCLUSIONS Despite the suppression of IH after non-polymeric paclitaxel-eluting stents compared with
bare-metal stents at 6 months, a “late catch-up” IH growth was found in the high-dose
patients at 2-year follow-up. (J Am Coll Cardiol 2006;48:2432–9) © 2006 by the American
ublished by Elsevier Inc. doi:10.1016/j.jacc.2006.08.033College of Cardiology Foundation
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an-stent restenosis secondary to intimal hyperplasia (IH)
as been the major limitation of coronary stenting (1,2).
edium-term results from several randomized clinical trials
ave shown that drug-eluting stents (DES) substantially
educe rates of angiographic restenosis and the need for
epeat revascularization compared to bare-metal stents
BMS) (3–5). However, there are concerns about the long-
erm efficacy (late restenosis) and safety (late thrombosis) of
ES (6,7) similar to intracoronary brachytherapy (8).
The ASPECT (ASian Paclitaxel-Eluting Stent Clinical
rial) was a 3-center, triple-blind, randomized, placebo-
ontrolled trial of nonpolymer-encapsulated paclitaxel-
oated stents to reduce in-stent restenosis (9). The intra-
From the Department of Medicine, University of Ulsan College of Medicine, Asan
edical Center, *Seoul and †GangNeung, Korea; ‡Cardiovascular Research Foun-
ation, New York, New York; and the §Washington Hospital Center, Washington,
C. This study was partly supported by Cardiovascular Research Foundation, Seoul,
orea, and Cook Cardiology; and by grants from the Korean Society of Circulation
nd the Korea Health 21 R&D Project, Ministry of Health & Welfare, Korea
0412-CR02-0704-0001).d
Manuscript received April 14, 2006; revised manuscript received August 1, 2006,
ccepted August 7, 2006.ascular ultrasound (IVUS) substudy was performed at a
ingle center (Asan Medical Center); 81 patients had
omplete after-stent implantation and 6-month follow-up
VUS showing a stepwise reduction in IH accumulation
ithin the stented segment (31  22 mm3 in the control
roup, 18  15 mm3 in the low-dose group, and 13  14
m3 in the high-dose group, p  0.001) (10). Given the
oncerns about the long-term results of DES, we report
he 2-year angiographic and volumetric IVUS analysis
rom the ASPECT study.
ETHODS
tudy population. The current 2-year follow-up angio-
raphic and IVUS analysis was a single-center (Asan Med-
cal Center) substudy of the ASPECT study. Single de novo
esions in 177 patients were randomized to placebo or 1 of
doses of paclitaxel (low dose: 1.28 g/mm2 stent surface
rea; high dose: 3.10 g/mm2 for overall doses of 54 to 60 g
nd 130 to 146 g, respectively, depending on stent
iameter). SupraG stents (Cook Cardiology)—a 316L
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December 19, 2006:2432–9 Two-Year Follow-Up After Paclitaxel Coating Stenttainless-steel slotted-tube design 15 mm in length with
iameters from 2.5 to 3.5 mm—were used in this study. The
ook’s proprietary paclitaxel coating process was used to
ond paclitaxel to the abluminal surface of the stents
ithout the use of a polymer. After release of paclitaxel, only
BMS remains (9). The details regarding drug-release
inetics have previously been described (9,11).
Patients were pretreated with aspirin plus either ticlopi-
ine or clopidogrel. Heparin was administered during the
rocedure according to standard practice. Glycoprotein
Ib/IIIa inhibitors were not used. After the procedure, in
ddition to aspirin indefinitely, ticlopidine or clopidogrel
as prescribed for 6 months. There was a single-center,
8-patient IVUS substudy of the ASPECT study in which
1 patients (25 placebo, 28 low-dose, and 28 high-dose
atients) had baseline and 6-month follow-up IVUS data
10). Excluding 5 patients (2 placebo, 2 low-dose, and 1
igh-dose patient) requiring target lesion revascularization
or restenosis at 6 months, 76 patients were enrolled in this
rospective 2-year follow-up study. All patients gave their
ritten informed consent. This study was approved by the
san Medical Center Institutional Review Board.
uantitative coronary angiographic (QCA) analysis.
sing the guiding catheter for magnification-calibration
nd an online system (ANCOR V2.0, Siemens, Erlangen,
ermany), minimal luminal diameter (MLD) of the lesion
nd diameters of the reference segments were measured
efore and after stenting and at 6-month and 2-year
ollow-up. Angiographic restenosis was defined as stenosis
f more than 50% of the luminal diameter. The late loss was
efined as the difference between in MLD after procedure
nd at follow-up.
VUS imaging and analysis. Intravascular ultrasound im-
ging was performed after intracoronary administration of
.2 mg nitroglycerin using motorized transducer pullback
0.5 mm/s) and a commercial scanner (SCIMED, Free-
ont, California) consisting of a 30 MHz transducer within
3.2-F imaging sheath.
Quantitative volumetric IVUS analysis was performed as
reviously described (10,12). Using computerized planim-
try, stent and reference segments were measured every 1
m. Reference segment external elastic membrane, lumen,
nd plaque and media (P&M  external elastic membrane
inus lumen) areas were measured over a 5-mm length
djacent to each stent edge and also averaged. Stent, lumen,
Abbreviations and Acronyms
BMS  bare-metal stents
DES  drug-eluting stents
IH  intimal hyperplasia
IVUS  intravascular ultrasound
MLA  minimum lumen area
MLD  minimal luminal diameter
QCA  quantitative coronary angiographynd IH (stent minus lumen) areas were measured every pmm within the stented segment; volumes were calculated
sing Simpson’s rule. The minimum lumen area (MLA)
as also measured. The primary end point of this analysis
as the change in IH volume between 6-month versus
-year follow-up.
tatistical analysis. All statistical analyses were performed
sing SPSS software (SPSS Inc., Chicago, Illinois). Cate-
orical data are presented as frequencies and compared with
hi-square statistics or Fisher exact test. Continuous vari-
bles are presented as mean  1 SD and compared using
npaired or paired t test and one-way or repeated measures
nalysis of variance with the Bonferroni correction for post
oc comparisons as appropriate. A p value 0.05 was
onsidered statistically significant.
ESULTS
linical and angiographic data. Long-term clinical
ollow-up data were available in all patients enrolled in the
VUS substudy of the ASPECT study. There were no
ardiac deaths, myocardial infarctions, or stent thromboses
etween 6-month and 2-year follow-up. Of 76 patients
nrolled in the current 2-year follow-up study, 2-year
ngiography and IVUS were not available in 20 patients
ecause of patient refusal (n  15) or comorbid conditions
n  5: old age 1, systemic vasculitis 1, contrast dye
naphylaxis 1, and malignancy 2). These 20 patients with-
ut 2-year follow-up angiography were clinically stable up
o 2 years. Of the 56 remaining patients, 1 high-dose patient
nderwent revascularization at 12-month follow-up and 2
atients (1 low-dose and 1 high-dose) had a total occlusion
attern of in-stent restenosis at 2 years follow-up precluding
ollow-up IVUS examination. Therefore, complete serial
after-stent implantation, 6-month follow-up, and 2-year
ollow-up) QCA data were available in 55 patients (72%):
7 of 23 placebo patients (74%), 18 of 26 low-dose patients
69%), and 20 of 27 high-dose patients (74%) (p  0.9).
omplete serial (after-stent implantation, 6-month follow-
p, and 2-year follow-up) IVUS data were available in 53
atients (70%): 17 of 23 placebo patients (74%), 17 of 26
ow-dose patients (65%), and 19 (70%) of 27 high-dose
atients (65%) (p  0.8).
As reported previously, baseline clinical characteristics
ere similar among the 3 groups (Table 1). No differences
xisted in baseline characteristics when comparing patients
ith and without 2-year angiographic follow-up in the
verall IVUS cohort, with the exception of smoking (p 
.021). Angiographic measures are shown in Table 1.
ngiographic data were also similar between patients with
nd without 2-year follow-up in the overall IVUS cohort,
xcept that 6-month MLD was larger in patients with
-year follow-up (2.3  0.7 mm vs. 1.6  0.9 mm, p 
.001). Reference vessel diameter and before- and after-
rocedure MLD were similar among the 3 groups. Six-
onth QCA MLD was significantly smaller in placeboatients compared with paclitaxel-eluting stent patients
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Two-Year Follow-Up After Paclitaxel Coating Stent December 19, 2006:2432–91.9  0.6 mm in placebo patients vs. 2.5  0.6 mm in
ow-dose patients, p  0.023; vs. 2.6  0.5 mm in high-dose
atients, p  0.006). However, these differences were not
aintained at 2-year angiographic follow-up, at which time
he angiographic MLD measured 2.3  0.6 mm, 2.3  0.7
m, and 2.0 0.8 mm in placebo, low-dose, and high-dose
atients, respectively (p  0.4). Late lumen loss during the
rst 6 months was significantly larger in placebo patients
0.8  0.7 mm in placebo patients vs. 0.5  0.6 mm in
ow-dose patients, p  0.3; vs. 0.3  0.5 mm in high-dose
atients, p  0.041). Conversely, late lumen loss between 6
onths and 2 years follow-up was0.4 0.5 mm in placebo,
able 1. Baseline Characteristics
Total Pla
umber of patients 55
ge (yrs) 57  9 56
ale gender, n (%) 42 (76) 13
iabetes mellitus, n (%) 6 (11) 2
ypercholesterolemia, n (%) 4 (7) 1
ypertension, n (%) 21 (38) 4
urrent smoking, n (%) 23 (42) 6
linical presentation, n (%)
Stable angina 24 (44) 7
Unstable angina 17 (31) 7
MI 72 h 14 (26) 3
iseased vessels, n (%)
1 39 (71) 11
2 12 (22) 5
3 4 (7) 1
essel stented
LAD 27 (49) 7
RCA 15 (27) 6
LCX 11 (20) 4
Ramus 2 (4) 0
eference diameter, mm 2.9  0.4 2.9
inimum lumen diameter, mm
Before-intervention 0.6  0.3 0.6
After-intervention 2.8  0.4 2.7
6 months 2.3  0.7 1.9
2 years 2.2  0.7 2.3
inary restenosis at 2 yrs, n (%) 8 (15) 1
he p values indicate comparisons among the 3 groups in 2-year follow-up populati
LAD  left anterior descending, LCX  left circumflex, MI  myocardial infar
igure 1. Comparison of the cumulative distribution of the minimal lumi
igh dose) before and after stenting and at 6-month and 2-year follow-up. Minim
roup showed significant changes over time (p  0.001), and these serial chang.2 0.6 mm in low-dose, and 0.6  0.8 mm in high-dose
atients (p  0.001). In post-hoc analysis, there was more
ate lumen loss in low- and high-dose patients compared
ith placebo patients (p  0.038 and p  0.001, respec-
ively). Cumulative frequency distribution curves of the
LD before intervention, after procedure, and at follow-up
re shown in Figure 1.
At 2-year follow-up, the rate of restenosis was 6% in the
lacebo group, 11% in the low-dose group, and 25% in the
igh-dose group (p  0.3). One high-dose patient under-
ent revascularization after the 2-year follow-up. The other
atients were treated with medication because of the lack of
2-Year Follow-Up Population
Low Dose High Dose p Value
18 20
58  11 56  8 0.6
13 (72) 16 (80) 0.8
3 (17) 1 (5) 0.5
2 (11) 1 (5) 0.8
8 (44) 9 (45) 0.4
8 (44) 9 (45) 0.8
0.6
7 (39) 10 (50)
4 (22) 6 (30)
7 (39) 4 (20)
0.9
13 (72) 15 (75)
4 (22) 3 (15)
1 (6) 2 (10)
0.8
8 (44) 12 (60)
6 (33) 3 (15)
3 (17) 4 (20)
1 (6) 1 (5)
3.0  0.4 2.9  0.4 0.3
0.6  0.3 0.5  0.3 0.4
3.0  0.4 2.9  0.3 0.2
2.5  0.6 2.6  0.5 0.004
2.3  0.7 2.0  0.8 0.4
2 (11) 5 (25) 0.3
RCA  right coronary artery.
ameter (MLD) between all 3 groups (A  placebo; B  low dose; C cebo
17
 8
(77)
(12)
(6)
(24)
(35)
(41)
(41)
(18)
(65)
(29)
(6)
(41)
(35)
(24)
(0)
 0.3
 0.4
 0.4
 0.6
 0.6
(6)nal di
al luminal diameter by quantitative coronary angiographic analysis in each
es of MLD were significantly different among the 3 groups (p  0.002).
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December 19, 2006:2432–9 Two-Year Follow-Up After Paclitaxel Coating Stentymptom or non-critical stenosis without the evidence of
yocardial ischemia.
VUS analysis. Intravascular ultrasound measurements are
hown in Table 2. After-intervention IVUS measurements
ere comparable between patients with and without 2-year
VUS follow-up in the overall IVUS cohort, with the excep-
ion of larger MLA in patients with 2-year follow-up (6.0 
.7 mm2 vs. 5.1  1.8 mm2, p  0.024). Six-month IVUS
easurements showed more favorable MLA (in-stent: 4.5 
.7 mm2 vs. 2.9 1.7 mm2, p 0.001; proximal reference: 7.7
3.0 mm2 vs. 5.5 2.3 mm2, p 0.004; and distal reference:
.6  2.2 mm2 vs. 5.4  2.4 mm2, p  0.041) and volume
able 2. Intravascular Ultrasound Measurements
Total P
umber of patients 53
fter intervention
Proximal reference segment
Mean EEM area, mm2 15.2  4.2 15.
Mean lumen area, mm2 8.0  2.8 7.
Mean P&M area, mm2 7.2  2.8 7.
Stented segment
Stent volume, mm3 109  27 10
Lumen volume, mm3 109  27 10
IH volume, mm3 0.4  2.8
Minimum lumen area, mm2 6.0  1.7 5.
Distal reference segment
Mean EEM area, mm2 12.3  4.3 12.
Mean lumen area, mm2 6.9  2.5 7.
Mean P&M area, mm2 5.3  2.7 4.
ix-month follow-up
Proximal reference segment
Mean EEM area, mm2 14.8  4.0 14.
Mean lumen area, mm2 7.7  3.0 7.
Mean P&M area, mm2 7.2  2.3 7.
Stented segment
Stent volume, mm3 108  27 10
Lumen volume, mm3 92  26 8
IH volume, mm3 16  15 2
Minimum lumen area, mm2 4.5  1.7 3.
Distal reference segment
Mean EEM area, mm2 12.1  3.9 11.
Mean lumen area, mm2 6.6  2.2 6.
Mean P&M area, mm2 5.4  2.4 5.
wo-year follow-up
Proximal reference segment
Mean EEM area, mm2 14.5  3.5 14.
Mean lumen area, mm2 8.2  2.8 7.
Mean P&M area, mm2 6.4  2.1 6.
Stented segment
Stent volume, mm3 107  26 10
Lumen volume, mm3 85  26 7
IH volume, mm3 22  15 2
Minimum lumen area, mm2 4.1  1.7 3.
Distal reference segment
Mean EEM area, mm2 11.9  3.6 11.
Mean lumen area, mm2 6.4  2.2 6.
Mean P&M area, mm2 5.5  2.3 5.
he p values indicate analysis of variance among the 3 groups in 2-year follow-up p
s. high dose. †p  0.018 placebo vs. low dose and p  0.030 placebo vs. high dos
EEM  external elastic membrane; IH  intimal hyperplasia; P&M  plaque astent: 108 27 mm3 vs. 94 29 mm3, p 0.032; lumen: 92 Q26 mm3 vs. 65  30 mm3, p  0.001; IH: 16  15 mm3
s. 29  22 mm3, p  0.006) in patients with 2-year IVUS
ollow-up because patients with severe obstruction needing
epeat intervention were excluded for long-term 2-year study.
After-intervention stent and reference measurements
ere similar among the 3 groups. There was a decrease in
umen volume and an increase in IH volume at 6 months
ollow-up in all 3 groups (p  0.001 for all comparisons).
owever, with increasing doses of paclitaxel, there was less
H accumulation within the stented segment (23 18 mm3
n placebo vs. 14  11 mm3 in low-dose, p  0.148; vs.
0  12 mm3 in high-dose stents, p  0.016). Like the
2-Year Follow-Up Population
Low Dose High Dose p Value
17 19
.5 17.4  4.6 13.5  3.0 0.1
.3 9.9  3.7 6.9  1.8 0.031
.4 7.4  2.8 6.6  2.1 0.6
8 117  29 105  25 0.4
7 117  29 105  25 0.3
0 0 0.4
.8 6.5  1.8 5.8  1.5 0.4
.2 12.3  4.9 12.5  4.2 1.0
.3 7.0  2.7 6.8  2.6 0.9
.1 5.3  3.0 5.7  2.3 0.8
.6 16.2  5.8 14.0  3.0 0.4
.1 8.9  4.4 7.3  2.2 0.3
.9 7.3  2.5 6.6  1.6 0.6
7 115  30 105  24 0.4
3 100  31 95  22 0.093
8 14  11 10  12 0.017*
.4 5.1  2.0 4.9  1.3 0.010†
.9 12.2  4.4 12.2  3.9 1.0
.6 6.8  2.4 6.5  2.7 1.0
.0 5.4  2.4 5.7  2.0 0.6
.4 15.7  4.8 13.7  2.2 0.4
.5 9.2  4.0 7.7  2.0 0.4
.6 6.5  2.3 5.9  1.3 0.7
6 113  29 105  24 0.5
5 95  28 82  25 0.142
9 18  10 23  14 0.4
.6 4.7  1.8 3.8  1.7 0.2
.6 12.0  4.1 11.9  3.6 0.9
.9 6.5  2.1 6.2  2.6 0.9
.7 5.5  2.6 5.7  1.8 0.6
ion. Post hoc comparisons: *p  0.148 placebo vs. low dose and p  0.016 placebo
dia.lacebo
17
4  4
7  2
6  3
5  2
4  2
1  5
8  1
1  4
1  2
9  3
7  3
1  2
6  2
4  2
1  2
3  1
5  1
9  3
8  1
1  3
5  3
8  2
6  2
3  2
8  2
5  1
7  1
7  3
5  1
2  2
opulatCA MLD, the 6-month IVUS MLA was significantly
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Two-Year Follow-Up After Paclitaxel Coating Stent December 19, 2006:2432–9maller in placebo patients compared with paclitaxel-eluting
tent patients (3.5  1.4 mm2 in placebo vs. 5.1  2.0 mm2
n low-dose stents, p  0.018, and vs. 4.9  1.3 mm2 in
igh-dose stents, p 0.030). However, at 2-year follow-up,
here was no difference in IH volume (p  0.4) or MLA
p  0.2) among the 3 groups. Figure 2 shows the
omparison of the percent of IH (IH volume/stent volume)
nd the MLA at the 3 time points (after-intervention, 6
onths, and 2 years). The percent of IH was significantly
ifferent (p  0.005) at 6 months, but similar (p  0.2) at
-year follow-up among the 3 groups.
As shown in Table 3, there was a dose-dependent decrease
n IH volume accumulation (p  0.037) from after inter-
ention to 6-month follow-up: p 0.22 comparing placebo
o low dose and p  0.038 comparing placebo to high dose,
ut p  1.0 comparing low dose to high dose. There were
omparable results for measurements of MLA. However,
etween 6 months and 2 years, there was a dose-dependent
ncrease in additional IH volume accumulation (p  0.016),
specially among high-dose patients: p  1.0 comparing
lacebo to low dose, p  0.019 comparing placebo to high
ose, and p  0.074 comparing low dose to high dose.
here were similar results for measurements of MLA.
In these cohorts, there were no significant changes in
eference segment measurements whether analyzed as a
olume (Table 3) or millimeter by millimeter from the stent
dge (Fig. 3). Comparing the change of IH area among the
groups, the placebo group showed that a decrease in IH
rea from 6 months to 2 years occurred mainly within the
tented segment that had a lot of neointima at 6 months,
uggesting compaction of the neointima. In contrast, the
ncrease of neointima was uniform over the length of the
tent in the paclitaxel-coated stents, with more significant
igure 2. Comparison of the percent of intimal hyperplasia (IH) (A,B,C)
) and at 6-month (B and E) and 2-year (C and F) follow-up. The perce
t 2-year follow-up among the 3 groups.rowth in high-dose patients (Fig. 3). eISCUSSION
he current study demonstrated that despite the 6-month
uppression of IH after non-polymer-encapsulated
aclitaxel-eluting stents compared with BMS, there was a
late catch-up” of IH growth during the subsequent 18
onths. Although there was greater 6-month suppression
f IH within high-dose stents, this was followed by a greater
ncrease in IH at 2 years in the same high-dose stents.
elayed neointimal regrowth in the paclitaxel-eluting stent
roups was diffuse over the entire length of the stent.
onversely, the placebo group showed a partial compaction
f the neointima between 6 months and 2 years. These
ndings were in contrast with an early 6-month IH re-
ponse shown in the previous study (13).
Drug-eluting stents significantly reduce restenosis rates to
10% (3–5). However, there are limited data on efficacy
eyond 1 year follow-up. Recent angiographic and IVUS
eports from the “first-in-humans” study of the sirolimus-
luting stent demonstrated sustained efficacy 2 and 4 years
fter implantation (14,15). Also, in the IVUS substudy of
he TAXUS-II trial, polymer-based paclitaxel-eluting stents
howed persistent neointimal suppression between 6
onths and 2 years follow-up (16).
Conversely, previous animal studies have documented
hat late neointimal growth develops despite marked early
uppression of neointimal formation within DES compared
ith BMS (17,18). Carter et al. (17) showed that long-term
nhibition of neointimal hyperplasia after polymer-based
irolimus-eluting stents was not maintained, partly because
f inflammation and delayed cellular proliferation in the
orcine coronary model. Similar findings are observed in
reclinical animal study using polymer-coated palictaxel-
he minimal lumen area (D,E,F) among all 3 groups after stenting (A and
was significantly different (p  0.005) at 6 months, but similar (p  0.2)and tluting stents, showing not only dose-dependent reduction
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elayed healing and local toxicity after high-dose paclitaxel
ssociated with delayed neointimal growth (18).
One previous human trial with 7-hexanoyltaxol (QP2)-
luting polymer stents (QuaDDS, Quanam, Santa Clara,
alifornia) reported favorable angiographic results at 6
onths but a significant number of late, accelerated
n-stent restenoses after 12 months (19). It was suggested
hat delayed healing with persistent fibrin deposits and
arying degrees of inflammation might have caused the
elayed restenosis (20). The persistent inflammation and
able 3. Serial Changes for Each Intravascular Ultrasound Measu
Placebo
umber of patients 17
ost-intervention to 6-month follow-up
Proximal reference segment
Mean EEM area, mm2 0.7  2.3
Mean lumen area, mm2 0.6  1.4
Mean P&M area, mm2 0.1  1.5
Stented segment
Stent volume, mm3 1  6
Lumen volume, mm3 23  20
IH volume, mm3 22  17
Minimum lumen area, mm2 2.3  1.8
Distal reference segment
Mean EEM area, mm2 0.2  1.4
Mean lumen area, mm2 0.4  1.4
Mean P&M area, mm2 0.2  1.0
ix-month to 2-year follow-up
Proximal reference segment
Mean EEM area, mm2 0.2  1.7
Mean lumen area, mm2 0.7  1.4
Mean P&M area, mm2 1.0  1.3
Stented segment
Stent volume, mm3 2  5
Lumen volume, mm3 3  11
IH volume, mm3 1  13
Minimum lumen area, mm2 0.2  0.8
Distal reference segment
Mean EEM area, mm2 0.2  1.2
Mean lumen area, mm2 0.3  1.2
Mean P&M area, mm2 0.1  1.3
ost hoc comparisons: *p  0.220 placebo vs. low dose and p  0.038 placebo vs. hig
lacebo vs. low dose, p  0.046 placebo vs. high dose, and p  0.145 low dose vs. hi
ow dose vs. high dose; p  0.411 placebo vs. low dose, p  0.002 placebo vs. high
Abbreviations as in Table 2.igure 3. The serial changes in reference segment external elastic membrane (E
reas from 6-month to 2-year follow-up are shown (A  placebo; B  low doelayed healing process have been significantly associated
ith a later occurrence of restenosis (“late catch-up
henomenon”). A similar phenomenon has been also
bserved at long-term (3 to 5 years) follow-up in patients
ho were treated with intracoronary brachytherapy
21,22). These clinically relevant limitations of radiation
ave shortened the therapeutic applicability of intracoro-
ary brachytherapy for treating atheromatous coronary
rtery disease. However, despite concerns about the
ossibility that delayed vascular healing after DES im-
lantation is associated with delayed neointimal growth,
ent
Low Dose High Dose p (ANOVA)
17 19
1.1  1.7 0.5  1.3 0.1
1.0  1.8 0.4  1.1 0.056
0.1  1.0 0.1  1.2 0.9
2  11 0  11 0.8
17  15 10  18 0.115
14  11 11  12 0.037*
1.4  1.2 0.9  1.1 0.021†
0.1  1.0 0.3  1.8 0.9
0.2  1.1 0.3  1.7 0.9
0.1  0.9 0  1.0 0.9
0.5  1.1 0.3  1.3 0.9
0.3  1.1 0.4  1.0 0.8
0.8  0.9 0.7  0.8 0.9
2  6 0  6 0.5
5  9 13  14 0.035‡
4  7 13  14 0.016§
0.3  1.2 1.1  1.3 0.003
0.2  1.5 0.3  1.1 1.0
0.2  1.4 0.4  1.8 1.0
0.1  1.0 0  1.1 0.9
; †p  0.293 placebo vs. low dose and p  0.018 placebo vs. high dose; ‡p  1.000
e; §p  1.000 placebo vs. low dose, p  0.019 placebo vs. high dose, and p  0.074
, and p  0.122 low dose vs. high dose.rem
h dose
gh dosEM), plaque, and lumen and in intra-stent lumen and intimal hyperplasia
se; C  high dose). Measurements were made every 1 mm.
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he DES clinical studies.
The current IVUS substudy form th ASPECT study
emonstrated encouraging dose-dependent reduction of IH
t 6 months that was almost entirely eliminated at 2 years,
specially in patients receiving high-dose paclitaxel-eluting
tents. The precise mechanism for the development of late
H proliferation in paclitaxel-eluting stents remains elusive.
owever, dose-dependent late IH proliferation may be due
o delayed healing and the local vascular toxic effect of
igh-dose paclitaxel, which was suggested in the preclinical
tudy (18). Additionally, there is the possibility that uncon-
rolled and non-sustained drug delivery from a metal stent
ithout a polymer coating might have an influence on the
ong-term inhibition of neointimal hyperplasia. Non-
olymeric paclitaxel delivery used in the current study might
e the reason for the late progression of IH, especially at the
igher dose of paclitaxel. Therefore, extension of these
ndings to clinically available polymer-based paclitaxel-
luting stents is, at best, speculative.
Other clinical trials (DELIVER and ELUTES [Euro-
ean evaluation of pacliTaxel-Eluting Stent]) using a sim-
lar high dose of paclitaxel (2.7 to 3.0 g/mm2) and a
roprietary nonpolymeric coating process showed that
aclitaxel-coated stents significantly decreased late loss
nd/or subsequent restenosis 6 to 8 months after the
rocedure (11,23). Because the long-term results from the
ELIVER and ELUTES trials have not been reported, it
annot be predicted whether dose-dependent late IH re-
rowth after implantation of non-polymeric paclitaxel-
luting stents is unique to the ASPECT study.
The findings in the current study may not be directly
pplicable in other clinical trials of polymer- and
onpolymer-based paclitaxel- and sirolimus-eluting stents
wing to considerable differences in stent platforms; poly-
ers; and coated drugs, drug dose, and drug release kinetics.
owever, considering the fact that very modest but contin-
ed neointimal regrowth is found in the long-term
ollow-up of the “first-in-humans” study of the sirolimus-
luting stent and the TAXUS-II IVUS substudy (14–16),
urther investigations are needed to evaluate the clinical
ignificance of this phenomenon and the appropriate length
f follow-up in patients receiving DES.
Interestingly, patients in the current study showed a
enign clinical course during long-term follow-up, despite
he considerable number of angiographic restenoses. Our
ractice pattern is not to treat angiographic restenosis unless
he patient is symptomatic or has objective evidence of
yocardial ischemia.
Finally, the discrepancy between QCA MLD and IVUS
eointimal hyperplasia volumes, especially in the placebo
roup, deserves some comment. Quantitative coronary angiog-
aphy measures the MLD at the worst location regardless of its
xial location. The worst location can, in fact, shift during short
r long-term follow-up. Conversely, IVUS measures IH vol-me along the entire stent. Therefore, it is possible for QCA
LD to improve while IH volume progresses.
tudy limitations. This was a prospective analysis from a
ingle center. This study was a serial long-term follow-up study
f patients enrolled in the 6-month IVUS substudy of the
SPECT study. Although clinical data were available in all
atients, complete 6-month and 2-year serial angiographic and
VUS follow-up was limited. However, comparable baseline
linical demographics and angiographic and IVUS data before
nd after intervention and at 6 months indicate that the current
ohort is representative of the overall IVUS substudy. The
urrent observations are not necessarily applicable to the other
ES systems owing to possible selection bias, small patient
umbers in the current study, and the fact that this is a unique
evice. Also, the current patients may represents a “best-case
cenario” in the ASPECT study because of exclusion of
atients with major cardiac events or repeat intervention before
-year follow-up.
onclusions. Despite the marked 6-month suppression of
H after nonpolymer-encapsulated paclitaxel-eluting stents
ompared with BMS, the anti-proliferative effect was not
aintained in patients receiving high-dose stents at 2-year
ollow-up, suggesting the possibility of incomplete healing
nd/or local toxicity of nonpolymeric high-dose paclitaxel
elivery.
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